<?xml version="1.0" encoding="UTF-8"?>
<author-notes>
 <corresp id="cor1">
  <label>*</label>Address correspondence to Jean B. Nachega, Infectious Diseases and Microbiology, Graduate School of Public Health and Center for Global Health, University of Pittsburgh, 130 DeSoto St., Crabtree Hall A531, Pittsburgh, PA 15261. E-mails: 
  <email>jbn16@pitt.edu</email> or 
  <email>jnacheg1@jhu.edu</email>
 </corresp>
 <fn fn-type="COI-statement">
  <p>Disclaimer: The views and opinions expressed in this article are those from the authors and not of any government, organization, or institution.</p>
 </fn>
 <fn fn-type="COI-statement">
  <p>Disclosure: All authors have a specialist interest in emerging and reemerging pathogens and report no potential conflicts. J. J. M.-T. is leading the COVID-19 Task Force Response in the DRC. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p>
 </fn>
 <fn fn-type="financial-disclosure">
  <p>Financial support: J. B. N. is an infectious disease internist and epidemiologist supported by U.S. National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases grant number 5U01AI069521 (Stellenbosch University Clinical Trial Unit of the AIDS Clinical Trial Group) as well as NIH/Fogarty International Center grant numbers 1R25TW011217-01 (African Association for Health Professions Education and Research) and 1D43TW010937-01A1 (University of Pittsburgh HIV Comorbidities Research Training Program in South Africa) and is a coprincipal investigator of Together, an adaptive randomized clinical trial of novel agents for treatment of high-risk outpatient COVID-19 patients in South Africa supported by the Bill &amp; Melinda Gates Foundation. A. Z. is a coprincipal investigator of the Pan-African Network on Emerging and Re-Emerging Infections (PANDORA-ID-NET; 
   <ext-link ext-link-type="uri" xlink:href="https://www.pandora-id.net/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.pandora-id.net/</ext-link>) funded by the EU Horizon 2020 Framework Program for Research and Innovation and is in receipt of an NIH Research Senior Investigator award. A. R. is the director of the UCLA-DRC Health Research and Training Program funded by the Bill &amp; Melinda Gates Foundation (OPP1195609), FDA, and Faucett Catalyst Fund.
  </p>
 </fn>
 <fn fn-type="present-address">
  <p>Authors’ addresses: Jean B. Nachega, Department of Medicine and Centre for Infectious Diseases, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, Department of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, and Department of Epidemiology, Infectious Diseases and Microbiology, Center for Global Health, University of Pittsburgh, Pittsburgh, PA, E-mail: 
   <email>jnachega@jhsph.edu</email>. Placide Mbala-Kingebeni, Department of Microbiology, Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo, E-mail: 
   <email>mbalaplacide@gmail.com</email>. John Otshudiema, World Health Organization Regional Office for Africa, Emergencies Program, COVID-19 Response, Epidemiological Surveillance Team, Democratic Republic of the Congo, E-mail: 
   <email>johnotokoye@gmail.com</email>. Linda M. Mobula, International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, and Ebola Response Team, Health, Nutrition and Population, Global Practice, World Bank Group, Washington, DC, E-mail: 
   <email>mmobula@worldbank.org</email>. Wolfgang Preiser, Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, and National Health Laboratory Service (NHLS), Cape Town, South Africa, E-mail: 
   <email>preiser@sun.ac.za</email>. Oscar Kallay, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium, E-mail: 
   <email>oscar_kallay@yahoo.fr</email>. Susan Michaels-Strasser, Human Resources for Health (HRH), Columbia University Mailman School of Public Health, New York, NY, E-mail: 
   <email>sm3966@cumc.columbia.edu</email>. Joel Breman, American Society of Tropical Medicine and Hygiene, Oakbrook Terrace, IL, and National Institutes of Health, Fogarty International Center, Bethesda, MD, E-mail: 
   <email>bremanj@mail.nih.gov</email>. Anne W. Rimoin, Department of Epidemiology, University of California, Los Angeles (UCLA), Fielding School of Public Health, Los Angeles, CA, E-mail: 
   <email>arimoin@gucla.edu</email>. Justus Nsio, Department of Epidemiology, National Institute of Biomedical Research, COVID-19 Response Task Team, Kinshasa, Democratic Republic of the Congo, E-mail: 
   <email>justusnsio@yahoo.fr</email>. Steve Ahuka-Mundeke, National Institute of Biomedical Research, COVID-19 Response Task Force, Kinshasa, Democratic Republic of the Congo, and Department of Medical Virology and Microbiology, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, E-mail: 
   <email>amstev04@yahoo.fr</email>. Alimuddin Zumla, Division of Infection and Immunity, Department of Infection, Centre for Clinical Microbiology, University College London, London, UK, E-mail: 
   <email>a.zumla@ucl.ac.uk</email>. Jean-Jacques Muyembe Tam-Fum, Department of Medical Microbiology and Virology, National Institute of Biomedical Research (INRB), Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, E-mail: 
   <email>jjmuyembet@gmail.com</email>.
  </p>
 </fn>
 <fn fn-type="equal" id="fn1">
  <label>†</label>
  <p>These authors contributed equally to this work.</p>
 </fn>
 <fn fn-type="equal" id="fn2">
  <label>‡</label>
  <p>These authors contributed equally to this work.</p>
 </fn>
</author-notes>
